In 1458 patients with CKD stage 4-5 or on dialysis at high cardiovascular risk, rivaroxaban 2.5 mg twice daily vs placebo did not reduce CV death, MI, stroke or PAD events (22.6% vs 20.7%; HR 1.09) and raised major bleeding (8.8% vs 6.0%). Stopped early.
RCTn = 1,458
Badve et al. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial